Anti-Doping
**DRUG TESTING**

*What Substances Do I Get Tested For?*

If you are competing in USATF sanctioned events, IAAF sanctioned events, or USOC sanctioned events (Pan-American Games, Olympic Trials, World University Games, etc.), you are subject to drug testing.

Do not take substances such as ephedrine and amphetamines/stimulants or anabolic steroids (substances such as testosterone, DHEA, and androstenedione); engage in prohibited techniques such as using diuretics, epitestosterone, EPO and probenecid; take “masking” agents; or engage in blood doping.

The list of prohibited substances is included in the IAAF’s Procedural Guidelines for Doping Control and the World Anti-Doping Agency (WADA) Code Prohibited List. It is important to remember, however, that these lists provide only examples of prohibited substances and may be amended or updated from time to time, it is imperative that you check the IAAF and WADA websites periodically – [www.iaaf.org](http://www.iaaf.org) or [www.wada-ama.org](http://www.wada-ama.org).

You should always remember to call the USADA Drug Reference Hotline or access the USADA ([www.usada.org](http://www.usada.org)) or the IAAF website ([www.iaaf.org](http://www.iaaf.org)) before consuming any substance, medication or nutritional supplement. The number for the USADA Drug Reference Line in the United States is 800-233-0393 or outside the U.S. is 719-785-2020. Athletes can also search USADA’s Drug Reference online database 24-hours a day by visiting [www.usada.org/dro](http://www.usada.org/dro).

Athletes who test positive in any one of these categories are subject to sanctions imposed pursuant to USATF’s Regulation 10. The penalty for a first time doping violation involving the use of stimulants is a public warning and a disqualification from the event in which the sample was taken (a second such offense will result in a two-year ban). The penalty for a first-time doping violation involving the use of anabolic steroids, amphetamines/stimulants, and/or utilizing a prohibited technique is a *minimum* two (2) year period of ineligibility. A second offense carries a lifetime period of ineligibility. USA Track & Field at its 2003 Annual Meeting passed bylaws changes calling for a lifetime ban for first-time steroid offenses, but that penalty is not observed by USADA. However, for each individual steroid case, USATF formally requests that USADA impose a lifetime ban for first offenses. Since then, penalties for first-time offenses have varied, and have also included sanctions for so-called “non-analytical positives,” where evidence of drug use other than a doping test is used to administer a penalty. First-time penalties have been as high as 8 years, and the IAAF and WADA are currently considering increasing the first-time ban to 4 years.

USATF adheres to a strict liability policy with respect to doping control. This means that you are responsible for everything that you ingest, regardless of whether or not you knew it was prohibited, and you will be considered to have committed a doping violation if a urine sample you provide contains a prohibited substance.

Because the Food & Drug Administration does not require nutritional supplement manufacturers to disclose the contents of the supplement, many nutritional supplements contain substances that are banned by WADA and/or the IAAF. As a result, you are advised not to ingest any supplement unless you are 100% certain that they do not include a prohibited substance.
There are, however, certain exceptions to this strict liability policy. Athletes who have asthma or other conditions that necessitate the use of a prohibited substance may apply, **prior to entering a competition**, to the IAAF and USADA for a medical exemption. The requirements for obtaining a medical exemption and/or waiver can be obtained by contacting the USADA (866.601.2632 or www.usada.org), or the IAAF (www.iaaf.org) directly, or by contacting the USATF Elite Athlete Programs and Melissa Beasley at 317-713-4650 or www.usatf.org/elite.

Those athletes who are receiving medical treatment for Attention Deficit Disorder (ADD) must understand that the IAAF has stated that for athletes who “require amphetamine medication for the treatment of an ADD condition, such medication should be taken under close medical supervision and on a schedule designed to ensure that the athletes do not compete with amphetamines present in their bodies. If an athlete tests positive for amphetamines at a competition, it will be treated as a finding of a prohibited substance in accordance with the IAAF Rules.”

**How Do I Get Tested?**
You are subject to both in-competition drug testing and out-of-competition drug testing. In both cases only urine is collected and tested, although blood may be collected at any time.

Out-of-competition testing occurs outside competitions and may be conducted by either representatives of USADA, WADA or the IAAF. If you are ranked among the top 50 in the World or one of the top fifteen (15) performers in your respective event domestically, you are subject to out-of-competition drug testing. The rankings are provided by the IAAF, Track and Field News and the USATF Long Distance Running Department. The IAAF rankings can be found on their website (www.iaaf.org). **If you are subject to out-of-competition testing, you are responsible for keeping USADA, the IAAF and USATF informed of your most current address as well as any temporary address changes.** Athletes are required to submit a 60-minute window to USADA on a daily basis of when they are available and accessible for testing. All updates and submissions to USADA must be done electronically – either by logging on to the USADA website at www.usada.org/ae, by emailing USADA at update@usada.org or by texting USADA at text@usada.org.

USADA contacts every athlete who enters into the drug testing program and requires that you complete USADA location and training information forms electronically. If you think that you may be ranked as one of the top performers (World Top 50 or Top 15 US) in your event and we have not contacted you, please contact USATF immediately. We will be happy to confirm whether you are in the drug testing pool. In addition, we can send you additional information regarding the Drug Testing Program and the substances prohibited by both the IAAF and the USADA.

Under the IAAF out-of-competition drug testing rules, any athlete competing and who is ranked among the top 20 in the World is subject to out-of-competition drug testing by them. The IAAF out-of-competition drug testing program is conducted pursuant to the provisions set forth in the IAAF Procedural Guidelines for Doping Control. (See www.iaaf.org or contact the USATF Elite Athlete Programs for a copy.)

However, regardless of the organization responsible for conducting the out-of-competition program, **it is important for athletes to know that out-of-competition drug testing can occur any time and any place.**
Collectors (representing either the IAAF or USADA) must identify him/her self to you as a “collector” and present identification before a sample can be collected. **If you refuse to submit to testing, you may be charged with a doping offense and prohibited from competing in USATF and IAAF events for a period of two (2) years.**

In-competition drug testing occurs at all USATF National Championships, Olympic Trials, World Championship trials, and other selected USATF sanctioned events. Drug chaperones will present notification forms and instructions to you if you have been selected for drug testing.

**Who Will Test Me?**
Because USATF is a member of both the USOC and the IAAF, and because both the USOC and the IAAF have drug testing programs, you are subject to drug testing under the auspices of by both organizations. (NOTE: USADA conducts drug testing on behalf of the USOC). However, regardless of the organization conducting drug testing, and regardless of the number of times you have been selected for in-competition or out-of-competition drug testing, you must provide a sample if selected for drug testing. An unexcused failure to provide a sample could result in the sample being considered positive for a prohibited substance and a two (2) year penalty may be imposed.

**What Happens If A Sample Tests Positive For A Prohibited Substance?**
USADA handles all aspects of the disciplinary process if a sample tests positive. If USATF is notified by the IAAF or another relevant authority other than USADA that a sample has tested positive for the presence of a prohibited substance, USATF notifies the athlete and informs USADA, who handles the remainder of the process.

Athletes found to have committed a doping violation will be subject to the following penalties for stimulants:

1) A first offense using a stimulant is a **public warning**, a disqualification from the event in which the sample was taken, and a loss of any award or prize money received.

2) A second offense for stimulant use is a **two (2) year** period of ineligibility, and

3) A third offense is a **lifetime ban**.

The following penalties are for the use of anabolic steroids, certain amphetamines or prohibited techniques:

1) A first offense is a **minimum two (2) year** period of ineligibility.

2) A second offense for the above-mentioned substances is a **lifetime ban**.

**Remember:**
Before taking any substance or medication, call:

1-800-233-0393 USADA Drug Reference Line

*It is your responsibility and your career*

For more information or if you wish to request a packet of information concerning drug testing, please contact Associate Director of Elite Athlete Relations Melissa Beasley.
International Standard for Testing:  
WHAT THESE CHANGES MEAN TO YOU

There are significant changes in the WADA Code which USADA is required to implement. You will notice changes to how USADA's anti-doping procedures will be carried out, especially regarding whereabouts information. Below is a brief overview of these changes and how they may impact you as an athlete in USADA’s Registered Testing Pool (RTP) - formerly called the Out-of-Competition Testing Pool.

WHEREABOUTS FILING AND ONLINE SUBMISSIONS

The name of the process for filing your whereabouts information has changed from Athlete Location Forms (ALF) to Whereabouts Filing.

Additionally, beginning 1st Quarter 2009, your whereabouts information can only be filed through the USADA online system. USADA is eliminating the paper reporting option for submitting a Whereabouts Filing. Requiring online submissions will benefit you in the following ways:

1. Submitting a Whereabouts Filing online will help ensure that you file your whereabouts information properly, rather than forgetting one or two dates in the quarter and, therefore, receiving a Whereabouts Failure (see Whereabouts Failures – Missed Tests & Filing Failures)

2. As WADA is requiring more information from you, a hardcopy form would be 6-10 pages in length. The online submission of this information decreases the amount of paper needed to properly submit your Whereabouts Filing.

The new deadlines for submitting your Whereabouts Filing will be:

1st Quarter – December 31  
2nd Quarter – March 31  
3rd Quarter – June 30  
4th Quarter – September 30

With the new deadlines set just one day prior to the start of the new quarter, USADA hopes that athletes will know more of their whereabouts information prior to submission of their Whereabouts Filing. However, any athlete who has not submitted a complete Whereabouts Filing with USADA by the deadline date will be subject to a Filing Failure (see Whereabouts Failures).

Updates to your quarterly whereabouts information may be made through your whereabouts on-line account, by e-mail or text.
If you need to set up an account or need assistance with your username and password, you can call 1-866-601-2632 or e-mail formsadmin@usada.org.

REQUIRED WHEREABOUTS FILING INFORMATION
Beginning January 1, 2009, the information you provide for your Whereabouts Filing will remain consistent with what you currently provide. Additionally, the new standards require that you specify a 60-minute time-slot, every day, with a specific location and address at which you can be located for testing. This time can vary from day to day, but must fall within the 6AM to 11PM time range. If you are not at the location specified in your Whereabouts Filing during the 60-minute time-slot, and a Doping Control Officer attempts to notify you for Out-of-Competition Testing, it will be pursued as a Missed Test. You are accountable for being available during the entire 60-minute time-slot.

The purpose of requiring athletes to provide whereabouts information for a 60-minute time-slot every day is to strike a balance between the need to locate an athlete for testing and the impracticality and unfairness of making athletes potentially accountable for a Missed Test every time they depart from their previously-declared schedule. You must update your Whereabouts Filing to ensure that the information regarding your training, competitions, and regularly scheduled activities and 60-minute time-slot is accurate.

With this change, you have more control over when and where you will be tested. Having to stipulate where you will be during a 60-minute time-slot every day means that you will have to be diligent about keeping your whereabouts information up-to-date. It is important to remember that the implementation of the 60-minute time-slot does not mean that you will only be tested within the 60 minutes. USADA or any other Anti-Doping Organization with the authority to test you could test you at any time.

WHEREABOUTS FAILURES - FILING FAILURES & MISSED TESTS
There are three ways you can receive a Whereabouts Failure:

1. You are not at the specified location during the 60-minute time-slot provided in your Whereabouts Filing when the Doping Control Officer attempts to notify and test you – this will be pursued as a Missed Test;

2. You do not file your Whereabouts Filing by the specified deadline – this is known as a Filing Failure; and

3. You do not file accurate or complete information to USADA in your Whereabouts Filing regarding your 60-minute time-slot or any other required whereabouts information– this could be known as a Filing Failure.

Three (3) Whereabouts Failures, which includes any combination of Missed Tests and Filing Failures recognized by any Anti-Doping Organization that has gover-
nance over testing you (including an International Federation, WADA or USADA), in any rolling 18-month period, will result in an Anti-Doping Rule Violation (ADR V). This enhances unity between the different anti-doping organizations within your sport. With this unity, however, it is important to remember that any Missed Test previously received by any Anti-Doping Organization is subject to be shared with other Anti-Doping Organizations with authority to test you.

**PHONE CALLS**

Beginning January 1, 2009, the new rules will no longer allow phone calls to be made in an attempt to locate you, as is currently practiced in the United States. Being diligent about being available during your 60-minute time-slot and updating your Whereabouts Filing whenever plans change will be critical to avoiding a Whereabouts Failure.

This new rule will allow Anti-Doping Organizations world-wide to conduct TRUE no-notice testing. Additionally, this new routine will help give you control over these whereabouts obligations, which has not always been the case on a universal basis.

**COLLECTION REQUIREMENTS**

Currently, when notified for an In-Competition or Out-of-Competition test, athletes are required to submit 85 mls of urine to process the sample.

After January 1, 2009, the minimum amount of urine needed to process a sample will increase to 90 mls. Additionally, the pH of the sample will no longer be evaluated.

Change can be daunting, but in the end, these new measures will streamline the current processes, and make things easier for you, the athlete. It is important to remember that these changes are being implemented with athletes worldwide and will help to harmonize anti-doping efforts around the globe.

*If you have any questions, please contact Kelli Feltmann, USADA Olympic Education Manager, at 719-785-2023 or via e-mail at kfeltmann@usada.org.*
Changes to the Prohibited List  
Effective January 1, 2009

The World Anti-Doping Agency (WADA) has published the 2009 Prohibited List, which goes into effect January 1, 2009. Below is a summary of the pertinent changes. For a full copy of the list, please visit the WADA website at www.wada-ama.org.

As an introduction to the 2009 Prohibited List changes, it is important to note that as of January 1, 2009, most Prohibited Substances shall be considered “Specified Substances.”

These changes provide greater flexibility with respect to sanctions. When an athlete can establish that the substance involved in the adverse analytical finding was not intended to enhance performance, the sanction may be reduced.

Those substances remaining as

Non-Specified Substances include:

• Anabolic agents

• Hormones and related substances

• Agents modifying myostatin function

• Those stimulants classified as “Non-Specified”

Other notable changes include:

Substances and Methods prohibited at All Times (In- and Out-of-Competition)

S1. Anabolic Agents
Epistosterone has been reclassified as an Anabolic Androgenic steroid since it is an isomer of testosterone. With this change, epistosterone will maintain its status as a prohibited substance.

S3. Beta-2 Agonists
The Abbreviated Therapeutic Use Exemption that previously applied to salbutamol, salmeterol, terbutaline and formoterol has been eliminated. The procedure for the use of any beta-2 agonist now depends on the level of the athlete, according to the International Standard for Therapeutic Use Exemptions (see page 6). Albuterol (salbutamol) concentrations greater than 1000 ng/mL in the urine will result in an adverse analytical
finding unless the athlete can prove that the abnormal result was the consequence of the use of a therapeutic dose of inhaled salbutamol. Any request for a TUE must be filed 21 days in advance of the use of the medication under the rules of sport that apply.

**S5. Diuretics and Other Masking Agents**

Alpha-reductase inhibitors, such as finasteride and dutasteride, are no longer prohibited. They have been rendered ineffective as masking agents by newer techniques to analyze steroid profiles.

**M2. Chemical and Physical Manipulation**

The use of intravenous (IV) infusions continues to be prohibited and thus requires a TUE, except in the management of surgical procedures, medical emergencies or clinical investigations.

An intravenous infusion is defined as the delivery of fluids into the body through a vein using a needle or similar device. Injections with a syringe are not prohibited as a method, if:

- a. The injected substance is not prohibited, and
- b. If the volume does not exceed 50 mL.

**S6. Stimulants**

Stimulants are now separated into two categories: Specified and Non-Specified Stimulants. When deciding how to categorize stimulants, WADA took into account many factors including the ability to enhance performance, the risk to health of athletes, the general use in medications, and their legal or controlled status.

**S9. Glucocorticosteroids**

Glucocorticosteroids continue to be separated into three categories:

- a. For oral, intravenous, intramuscular, and rectal routes - a Therapeutic Use Exemption is required.
- b. For intra-articular, periarticular, peritendinous, epidural, intradermal, and inhalation routes – a Declaration of Use is required.
- c. Topical preparations for treatment of ear, mouth, skin, eye, and nose conditions - are permitted and require no further documentation. Iontophoresis and phonophoresis are permitted and require no additional documentation.
IMPORTANT POINTS TO REMEMBER

1. Beta-2 agonists are prohibited both In- and Out-of-Competition. Salbutamol, salmeterol, formoterol and terbutaline require a Therapeutic Use Exemption (TUE). Procedures for the use of a beta-2 agonist depend on the level of the athlete.

2. IV infusions are prohibited In- and Out-of-Competition with exceptions.

3. The use of Glucocorticosteroids by inhalation or local injection requires a declaration on the Doping Control Official Record and medical documentation.

4. Glucocorticosteroids used as dermal (topical, iontophoresis, phonophoresis), eye drops, ear drops, nasal sprays and mouth (buccal) treatments are permitted and do not require a TUE.

5. Use of pure oxygen is prohibited.

6. The substances listed in the 2009 Monitoring List are not prohibited and their presence in the body will not result in a doping violation. Pseudoephedrine and caffeine are both on the monitoring list.

The 2009 Wallet Card and 2009 Guide to Prohibited Substances and Methods of Doping will be made available to all athletes in USADA’s RTP and will be provided to all National Governing Bodies. Copies of these publications, which will be effective January 1, 2009, will be available for download from USADA’s website. The current Wallet Card and Prohibited Guide can be found at:

Wallet Card:
www.usada.org/go/walletcard

Guide to Prohibited Substances:
www.usada.org/go/prohibitedguide

For more information, please contact the Therapeutic Use Exemption department at 719-785-2045 or via e-mail at TUE@usada.org.
International Standard for TUE: WHAT THESE CHANGES MEAN TO YOU

Like anyone, athletes may have illnesses or conditions that require them to take particular medications. In some cases, these medications may fall under the Prohibited List. If so, a Therapeutic Use Exemption (TUE) may give the athlete authorization to take the needed medication while participating in sport.

Coming with the International Standards of Therapeutic Use Exemptions (ISTUE) revisions in 2009, there will be key differences of which athletes need to be aware. Below, we have provided a summary of these changes and also listed helpful TUE resources. It will also be necessary to check with the appropriate International Federation (IF) as to how they are handling the changes, especially in cases where the IF is responsible for granting the TUE.

First, how does an athlete know whether a medication is safe to take…

Drug Reference Resources: When considering taking a pharmaceutical medication, athletes need to know whether the product is prohibited or permitted. USADA provides four helpful ways to determine if a substance is permitted or not:

• Drug Reference Online (DRO): www.usada.org/DRO is a valuable resource with a comprehensive search function, by name of medication – whether by brand name or generic — to determine its status.

• Drug Reference Line (DRL): Allowing athletes to call in and receive expert advice on the status of a medication, this toll-free number (800-233-0393) is operated Monday-Friday 9AM-4PM Mountain Standard Time.

• Guide to Prohibited Substances and Prohibited Methods of Doping: A comprehensive booklet providing a detailed summary of the WADA annual Prohibited List.


Abbreviated TUE

The Abbreviated TUE will no longer be a part of the TUE process. All uses of prohibited medications and substances will require a TUE for medications.

There is a grace period, however: Athletes with a current Abbreviated TUE will have until their Abbreviated TUE expires or December 31, 2009 (whichever occurs first) to re-apply for a TUE. Those athletes who currently have an Abbreviated TUE will receive a letter in the near future elaborating on the necessary steps during this transition period. As mentioned above, it is necessary to consult with the appropriate IF for their specific rules governing Abbreviated TUE transitions.
This applies specifically to two types of substances: beta-2 agonists and glucocorticosteroids.

**Beta-2 Agonists**

The use of inhaled formoterol, salbutamol, salmeterol and terbutaline will require advance declaration on the USADA website, a TUE, and documentation on the “Declaration of Use” section of the Doping Control Official Record at the time of testing. Obtaining a TUE for a beta-2 agonist will require more documentation than previously was needed for an Abbreviated TUE:

a. a medical file pertaining to the diagnosis and need to use the beta-2 agonists;

b. a comprehensive report of the clinical examination with specific focus on the respiratory system;

c. a report of spirometry, known as a Pulmonary Function Test (PFT), with the measure of the Force Expiratory Volume in 1 second (FEV1)

d. if airway obstruction is present, evidence of the spirometry being repeated after inhalation of a short-acting beta-2 agonist to demonstrate reversibility of bronchoconstriction;

e. in the absence of reversible airway obstruction, a bronchial provocation test is required to establish the presence of airway hyperresponsiveness; and

f. exact name, specialty, address (including telephone, email and fax) of examining physician.

**A Few Things To Note Regarding Beta-2 Agonists:**

- USADA will accept a PFT from as much as 4 years prior to the date of the application.

- It is important to remember that even with a current TUE on file, the presence of Salbutamol over 1,000 ng/mL may constitute an Adverse Analytical Finding.

**2. Glucocorticosteroids**

Glucocorticosteroids are commonly used to treat inflammation, asthma, and skin rashes. Depending on how the corticosteroid is used will determine if a TUE is required.

a. **Systemic Administration** - Corticosteroids used by oral, intravenous, intramuscular or rectal require the submission of a TUE.

b. **Non-Systemic or Inhalation Administration** - Corticosteroids used by intraarticular, periarticular, peritendinous, epidural, intra-dermal injections and inhalation will require notation on the “Declaration of Use” section of the Doping Control Official Record when tested, as well as on USADA’s website.
c. Topical Administration - Corticosteroids used as eye drops, nose drops, ear drops or iontophoresis are permitted and do not require the submission of a TUE.

Some Things Haven’t Changed

Where to Send a TUE: As before, USADA is trying to make the TUE process as easy as possible. Depending on the sport, in some instances USADA can authorize the TUE, and in other instances the athlete’s IF has to authorize the TUE. Nevertheless, we suggest that all US athletes (regardless of sport) submit their TUEs to USADA - we will forward them on to the appropriate organization for approval, if need be. With this, should there be a question or a delay in a response from an IF, we can easily follow-up and answer any questions an athlete may have.

Granting of A TUE: A TUE may be granted to an athlete if it meets the following conditions:

1. The athlete would experience a significant impairment to health if the use of the Prohibited Substance or Prohibited Method were to be withheld;

2. The therapeutic use of the Prohibited Substance or Prohibited Method would not provide an enhancement to performance other than what might be anticipated by a return to a state of normal health;

3. There are no reasonable, therapeutic alternatives to the use of the otherwise Prohibited Substance or Prohibited Method; and

4. The need for the Prohibited Substance or Prohibited Method is not a consequence to the prior non-therapeutic use of another prohibited substance or method.

Once a TUE is granted or denied, a letter and/or a certificate is issued to the athlete with a copy sent to the athlete’s National Governing Body, IF and WADA as appropriate. The decision of the TUE is recorded by USADA. If a TUE request is denied, an athlete has the right to appeal the decision.

TUEs and Sport: It is important to remember that anti-doping rules only govern conditions under which sport is played. The approval or denial of a TUE only pertains to the use of the medication in sport. USADA does not provide medical advice on the direction of an athlete’s care. Any decision to stop or start a treatment should be made in consultation with the athlete’s physician.

For any questions regarding the International Standard for TUEs, please contact USADA’s TUE Department, at 719-785-2045 or via email at tue@usada.org.

Please note that this message only highlights some of the changes in the International Standard for TUE and is not intended to be a detailed summary of the changes.
IAAF Therapeutic Use Exemptions (TUE)

Application Form

I hereby apply for approval for the therapeutic use of a prohibited substance or prohibited method on the IAAF Prohibited List

Please complete all sections in CAPITAL LETTERS or typing

- [ ] I am included in IAAF Registered Testing Pool
- [ ] Preparing for IAAF International Competition (which competition)

1. Athlete information

<table>
<thead>
<tr>
<th>First Name:</th>
<th>Last Name:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Female [ ] Male [ ]

<table>
<thead>
<tr>
<th>Discipline:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address:</th>
<th>City:</th>
<th>Country:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Postal Code:</th>
<th>Date of birth (dd/mm/yy):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tel.: (with international code)</th>
<th>Mobile:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail:</th>
<th>National Federation:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Medical information

- Diagnosis with sufficient medical information (see note 1):

- If a permitted medication can be used to treat the medical condition, provide clinical justification for the requested use of the prohibited medication:
3. Medication details

<table>
<thead>
<tr>
<th>Prohibited substance(s) (see Note 2):</th>
<th>Dose of administration</th>
<th>Route of administration</th>
<th>Frequency of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial name/Generic name</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e.g: Humuline©/Insulin/Salbutamol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intended duration of treatment (see Note 3):</th>
<th>Once only</th>
<th>Emergency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Or duration (week / month):</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional information: .................................................................

.................................................................

.................................................................

Have you submitted any previous TUE application?  yes  no  (tick appropriate box)

For which substance(s)? .................................................................

Organisation (to whom TUE application was sent) .................................................................

When (dd/mm/yy): ............

Result (attach previous TUE(s) where applicable): Approved  Not approved

Has the athlete’s National Federation Team Doctor been notified of this application?

Yes:  No:  

Name of National Federation’s Team Doctor (see Note 4): .................................................................
### 4. Medical practitioner’s declaration

I certify that the above-mentioned medication(s) for the above-named athlete is to be administered as the correct treatment for the above-named medical condition. I further certify that the use of alternative medications not on the IAAF Prohibited List would be unsatisfactory for the treatment of the above-named medical condition *(see Note 5)*.

Name, qualifications and medical speciality *(see Note 6)*: .................................................................

Address: ...........................................................................................................................................

City: .......................................................... State/Province: ......................... Country: .................................

Postal Code: ............ E-mail: .................................................................................................

Tel.: *(with international code)* ......................... Mobile: ............................................................

Signature of medical practitioner: ................................. Date: .................................................

### 5. Athlete’s declaration

I, ......................................................... certify that the information in section 1 above is accurate and that I am requesting for approval to use a prohibited substance or prohibited method in the IAAF Prohibited List.

I authorize the release of my personal medical information to the members of the IAAF Therapeutic Use Exemption Sub-Commission (IAAF TUESC), as well as to any other relevant persons (including, where applicable, WADA or IOC staff and/or members of the WADA or IOC Therapeutic Use Exemption Committees) who may be involved in the management, review or administration of my application in accordance with the IAAF Procedural Guidelines. I understand that, if I ever wish to revoke the right of the IAAF TUESC to obtain any health information on my behalf, I must notify my medical practitioner in writing of the fact. As a consequence of such a decision, I understand that I will not receive approval for a TUE (or renewal of an existing TUE).

I further authorise for the decision of the IAAF TUESC to be notified to other relevant organisations in accordance with IAAF Rule 34.9.

**Athlete’s signature:** ................................. **Date:** .................................

**Parent’s/Guardian’s signature:** ................................. **Date:** .................................

*(if the athlete is a minor, a parent or guardian shall sign together with or on behalf of the athlete)*
### Notes:

<table>
<thead>
<tr>
<th>Note 1</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence confirming the diagnosis must be attached and forwarded with this application. The medical evidence should include a comprehensive medical history, and the results of all relevant clinical examinations, investigations, specialist medical reports and imaging studies. Copies of original reports or letters should be included when possible. Evidence should be as objective as possible in the clinical circumstances and, in the case of non-demonstrable conditions, independent supporting medical opinion will assist this application.</td>
<td></td>
</tr>
</tbody>
</table>

For applications for the use of Beta-2-agonists only: To constitute a complete application, International-Level athletes must include the following documentation required by the IAAF Beta-2-Agonists Protocol:

1. Detailed Medical Records  
2. Provocation Test Results  
Both must be filled in on appendix A of this Application Form

Refer to the IAAF Beta-2 Agonists Protocol in the “athletes area” of [www.iaaf.org/antidoping](http://www.iaaf.org/antidoping) for further more detailed information on the documentation that is required.

<table>
<thead>
<tr>
<th>Note 2</th>
<th>Medication details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provide details concerning all medications or treatments. Provide both the commercial and generic name (INN) of the medication and specify the medication dose, the route of administration and the frequency of administration.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Note 3</th>
<th>Change of Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Note that a new TUE application is required for any change in prescription.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Note 4</th>
<th>National Federation Team Doctor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whenever possible, the National Federation Team Doctor should be notified of the application and the application should include a statement by the Team Doctor attesting to the necessity of the otherwise prohibited substance or prohibited method in the treatment of the athlete.</td>
<td></td>
</tr>
</tbody>
</table>

| Note 5 | If a permitted medication can be used in the treatment of the athlete’s medical condition, please provide clinical justification (on page 1) for the requested use of the prohibited medication. |

<table>
<thead>
<tr>
<th>Note 6</th>
<th>Name, qualifications and medical specialty</th>
</tr>
</thead>
<tbody>
<tr>
<td>For example: Dr AB Cook, MD FRACP, Gastro-enterologist. Dr JA Gonzalez, MBBS, FACSM, Sports Physician</td>
<td></td>
</tr>
</tbody>
</table>

**WARNING:** Incomplete Applications will be returned and will need to be re-submitted.
Appendix A

International Association of Athletics Federations

INHALED BETA-2-AGONIST APPLICATION FOR ASTHMA TREATMENT

Medical Records FORM

NAME OF THE ATHLETE: ______________________________________________
DATE OF BIRTH: _____________________ COUNTRY: ______________________

Diagnosis:

Age of onset:

Symptoms spontaneous or exercise related:
- Coughing during or post-exercise: Yes or No
- Shortness of breath: Yes or No
- Chest tightness: Yes or No

If yes, specify:

Identified triggering factors:

Past history of atopic disorders and/or childhood asthma:

Past physical examinations:

Results of skin prick tests or RAST to document the presence of allergic hypersensitivity:

Details of all consultations with qualified physicians in the treatment of asthma

Details of any attendance in hospital emergency departments for treatment or admission to hospital for treatment of acute exacerbation of asthma.

Details of the individual’s currently prescribed medication and any other medication prescribed in the past years, with particular details in the last 6 months.

Details of medication in the 3 months prior to provocation test:

<table>
<thead>
<tr>
<th>PFTesting information</th>
<th>Date of test: . . . . / . . . . / . . . .</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchodilator test: FEV₁ after bronchodilator: change compared to baseline: . . . . %</td>
<td></td>
</tr>
<tr>
<td>Methacholine challenge test</td>
<td>PD_{20} = . . . . . . . . µmol or . . . . . . . . . µg / PC_{20} = . . . . . . . . mg/mL</td>
</tr>
<tr>
<td>Eucapnic Voluntary Hyperpnoea: FEV₁ decrease of . . . . . . . . % within . . . . . . . . min</td>
<td></td>
</tr>
<tr>
<td>Exercise challenge: FEV₁ decrease of . . . . . . . . % within . . . . . . . . min</td>
<td></td>
</tr>
<tr>
<td>Hypertonic saline test: FEV₁ decrease of . . . . . . . . % within . . . . . . . . min</td>
<td></td>
</tr>
<tr>
<td>Mannitol test: FEV₁ decrease of . . . . . . . . % within . . . . . . . . min</td>
<td></td>
</tr>
</tbody>
</table>

Date:

Physician Name:

Physician Signature:
This Regulation 10 shall apply to all doping controls conducted on or after December 1, 2004.

A. Definitions: The following terms shall have the indicated meaning when used in this Regulation:

1. Doping: Doping is the occurrence of one or more of the violations defined as “doping” by IAAF Rules;
2. IAAF Protocol: Procedures set forth by the IAAF in its current “Procedural Guidelines for Doping Control,” or any successor publication. The IAAF procedural guidelines govern drug testing pursuant to the authority of the IAAF;
3. In-Competition Drug Testing: Drug testing that takes place during a selected competition;
5. Out-of-Competition Drug Testing: Drug testing that takes place when an athlete is not competing;
6. Prohibited Substances: The prohibited substances identified in either the WADA Anti-Doping Code or the IAAF Procedural Guidelines for Doping Control; and
8. USATF appeal of NABR decisions: Upon their own initiative, the President and CEO of USATF, after consultation with the General Counsel and Counsel to the Board, may initiate stay and appeal proceedings of any NABR decision and opinion which in their opinion clearly contravenes:
   a. Federal law: The Sports Act;
   b. USATF rules and regulations: USATF Bylaws, Operating Regulations, and/or Rules;
   c. IAAF rules and regulations: IAAF Rules and Regulations; or
   d. Other laws: Any applicable law.

B. Doping Control programs: USATF participates in several doping control programs which are conducted by USADA, the IAAF, and WADA. The IAAF may conduct doping control at USATF national championships competitions:

1. In-Competition Program (ICP): This program involves the testing of athletes during USATF sanctioned events for prohibited substances and techniques. The selection of athletes shall be pursuant to procedures established by either USADA or IAAF protocol. The organization responsible for drug testing will determine which protocol will apply; and
2. Out-of-Competition Program (OOC): This program involves the testing of selected athletes for prohibited substances and techniques. The OOC shall include a program of unannounced, walk-up testing. The selection of those athletes to be tested pursuant to the OOC program shall be determined by USADA, in conjunction with USATF, on the one hand, or by the IAAF, on the other hand. Each athlete who is eligible to be drug
tested, pursuant to this provision, is required to keep one (1) current address on file with the IAAF, USATF and USADA, and must notify the IAAF, USADA and USATF if the information on his/her previously submitted whereabouts or location form changes. It is each athlete’s responsibility to ensure that the IAAF, USADA, and USATF are informed of his/her whereabouts. Failure to adhere to this requirement may result in the athlete being charged with a doping offense. Those athletes wishing to be removed from the OOC program must meet the retirement requirements set forth in paragraph E below.

C. **Anti-doping program:** USATF shall participate in those anti-doping programs mandated by the IAAF and USOC under their respective constitutions, bylaws, and/or anti-doping rules. The Anti-Doping program shall apply to athletes and athlete support personnel, including but not limited to, coaches, trainers, managers, authorized athlete representatives, agents, team staff, officials, medical or para-medical personnel, or other persons working with or treating athletes participating in, or preparing for competition in, Athletics.

NOTE: The text of the applicable IOC, IAAF, USADA and/or USOC rules, protocols, and guidelines, relating to doping control are set forth in the attached see exhibits section of this handbook. These documents may be amended from time-to-time. Check the USATF website for updates or contact USATF’s Legal Department.

D. **Disciplinary procedures:** The disciplinary proceedings related to domestic positive drug tests of USATF athletes shall be conducted by USADA, as mandated in Chapter XXIV(2)(G) of the USOC Bylaws. When USATF is notified by the IAAF that an athlete’s “A” sample has tested or has been deemed positive for a prohibited substance, the matter shall be referred to USADA, by USATF, for a determination of whether a doping offense has occurred:

1. **Ineligibility:** If an athlete is found to have committed a doping offense or the individual waives the right to a hearing, the individual shall be declared ineligible to participate in Athletics competition, as provided below. In addition, if testing was conducted in competition, the athlete shall be disqualified from that competition and all competitions s/he competed in prior to the final decision of the hearing or appeals panel, and the result(s) amended accordingly. Ineligibility shall begin:

   a. from the date the period of ineligibility was imposed by an arbitration panel; or
   b. as otherwise determined by the IAAF; or

2. **Period of ineligibility:** For doping offenses in events conducted under the jurisdiction of the IOC, the penalties provided by the World Anti-Doping Code shall apply. In all other situations, an athlete or other person who commits a doping offense will be ineligible for the periods set forth below:

   a. Steroids: For a steroid offense under IAAF Competition Rule 32.2 (a) involving substance listed in S4-1 (a) and (b) of the World Anti-Doping Code, the suspension shall be for life, provided that such lifetime suspension does not violate any provision of the Sports Act, including the provision that requires that USATF
may “not have eligibility criteria related to amateur status or to participation in the Olympic Games, the Paralympic Games, or the Pan American Games that are more restrictive than those of the appropriate international sports federation;”

b. Other substances: For offenses involving all other substances or activities prohibited by IAAF Competition Rule 32.2, the penalties provided in IAAF Competition Rules 39 and 40 shall apply.

E. Retirement: Athletes wishing to retire from competition must complete and submit to USATF, prior to retirement, the “official” USATF retirement form. A copy of the retirement form is reproduced in the exhibits section of this handbook. Retired athletes are ineligible to return to competition for a minimum of twelve (12) months and must make themselves available for OOC drug testing for a period of six (6) months prior to retuning to competition.

F. Unexcused failure: An unexcused failure to provide a sample shall be considered as being the same as a confirmed “A” positive test for anabolic steroids, except that the athlete shall have the burden of proving to the panel a permissible excuse pursuant to the ICP or OCP, as the case may be.

G. Reinstatement: Reinstatement after doping suspensions shall be governed by IAAF Rules 40.12, 40.13, and 40.14. An athlete who has been declared ineligible and subsequently successfully completes reinstatement drug testing pursuant to IAAF Rule 40.12, shall be automatically reinstated upon issuance of a reinstatement letter by USATF or IAAF.

H. Notification of penalties: Upon a finding by a hearing panel that doping has occurred, USATF shall provide notice of the penalty(ies) to be imposed by means of a letter sent by facsimile transmission, regular mail, and/or by overnight mail.

I. Confidentiality of test results and doping offenses: Except as provided in paragraph J below, USATF shall only disclose such information related to drug testing matters as is appropriate and necessary to fulfill its obligations to the worldwide Olympic anti-doping effort, and in the event, only to the appropriate representatives of the relevant Olympic drug testing authorities – the USOC, USADA, the IAAF, WADA, and the IOC.

NOTE: If the athlete or the athlete’s representative breaches confidentiality, USATF’s response shall not constitute a breach of confidentiality.

J. Publication of doping test results: USATF shall publish, on a quarterly basis, the names of all USATF athletes who have tested negative during in-competition and out-of-competition drug testing. USATF shall publish the names of athletes who have been found to have committed a doping offense, at the conclusion of the entire disciplinary process; provided, however, that the publication by another Olympic drug testing authority of an athlete’s doping offense shall satisfy USATF’s publication obligation related thereto.
Part I. Definitions

1.1 Athlete(s) shall mean an individual who is a United States citizen and who has subjected himself or herself to the jurisdiction of USATF by (a) becoming a member of USATF, (b) competing in an event conducted under the auspices of USATF, (c) executing a competition entry form that notifies the Athlete that his/her participation in the competition subjects the Athlete to drug testing pursuant to the applicable rules of USATF, the IAAF, USADA or the USOC, or (d) applying for USATF or USOC athlete support.

1.2 IAAF shall mean the International Association of Athletics Federations, the world governing body for track and field, long distance running and race walking (Athletics).

1.3 Out-of-Competition (OOC) Drug Testing Pool shall mean:

A. For Track and Field: The top fifteen (15) U.S. Athletes listed by the IAAF as being among the top fifty (50) individual performers in the world in the Tested Events on the ranking lists set forth in Part V. If five (5) or more, but fewer than fifteen (15), athletes are so listed by the IAAF, all of those athletes shall constitute the Pool. If fewer than five (5) U.S. Athletes are so listed, the next highest ranking U.S. Athletes in that Event shall be added until the Pool is composed of at least five (5) Athletes. To the extent that the IAAF’s lists are inadequate for this purpose, USATF may use Track and Field News’ performer lists as a source for completing the OOC Pool.

B. For Road Racing: The top ten (10) individual U.S. Athletes listed by the IAAF as being among the top fifty (50) individual performers in the world in the Tested Events on the ranking lists as set forth in Part V. If fewer than ten (10) Athletes are so listed, the next highest ranking U.S. Athletes in that Event shall be added until the Pool is composed of at least five (5) Athletes. To the extent that the IAAF’s lists are inadequate for this purpose, USATF may use the Road Running Information Center or Track and Field News as a source for completing the OOC pool.
C. **For Cross Country:** The top ten (10) U.S. finishers in the USATF Winter Cross Country National Championships, as set forth in Part V-5.3. USATF shall notify USADA of the names of those athletes within seven days of the conclusion of the Championships. These athletes shall be placed in the OOC Pool in the subsequent testing quarter and shall be removed from the pool at the end of the fourth consecutive calendar quarter following inclusion in the OOC Pool, unless they are otherwise qualified to remain in the pool.

D. **For Indoor Only Events:** The top five (5) U.S. Athlete finishers at the U.S. Senior Indoor National Championships, as set forth in Part V-5.2. USATF shall notify USADA of the names of those athletes within seven days of the conclusion of the Championships. These athletes shall be placed in the OOC Pool in the subsequent testing quarter and shall be removed from the pool at the end of the fourth consecutive calendar quarter following inclusion in the OOC Pool, unless they are otherwise qualified to remain in the pool.

E. **Others:** Any athlete finishing in the top three positions in any Senior National Outdoor Championship. USATF shall notify USADA of the names of those athletes within seven days of the conclusion of the Championships. These athletes shall be placed in the OOC Pool in the subsequent testing quarter and shall be removed from the pool at the end of the fourth consecutive calendar quarter following inclusion in the OOC Pool, unless they are otherwise qualified to remain in the pool.

Any athlete establishing a World or American Record in an event listed in Part V. Such athlete shall be added to the OOC pool (if he or she is not already in the pool) by USATF’s notification to USADA within seven days of the performance.

USATF’s Athlete Services and Legal Departments shall jointly maintain the quarterly list of OOC Pool Athletes, which list shall be made available for public inspection upon request.

F. **USADA:** Pursuant to USADA’s Protocol For Olympic Movement Testing, Section 2, any athlete who is a member of USATF may be added to OOC pool by USADA, upon written notice to USATF and said athlete.

G. **USATF Additions:** USATF reserves the right to add, to the OOC Pool, any Athlete who is receiving athlete support from USATF or the USOC.

USATF’s Athlete Services Department shall maintain the quarterly list of OOC Pool Athletes, which list shall be made available for public inspection upon request.

H. **IAAF Additions:** The IAAF may add Athletes to its out-of-
competition drug testing pool based upon their athletic performances during the year. Any Athlete added to the IAAF’s out-of-competition drug testing pool may be added to the USATF/USADA out-of-competition drug testing pool. USATF and USADA will make every effort to add Athletes added to the IAAF’s out-of-competition drug testing pool to its domestic out-of-competition drug testing pool as specified in this Protocol.

1.4 Out-of-Competition Drug Testing (OOCT) shall mean the out-of-competition drug testing program which takes place outside competitions, and which is conducted by the United States Anti-Doping Agency on behalf of the USOC and all member national governing bodies of the USOC, as mandated by the Chapter XXIII of the USOC By-Laws.

1.5 **Tested Event** (or Events) shall mean the events designated in Part V below.

1.6 USATF shall mean USA Track & Field, Inc.

1.7 USADA shall mean the United States Anti-Doping Agency.

1.8 USOC shall mean the United States Olympic Committee.

**Part II. AUTHORITY**

2.1 This selection process is adopted pursuant to USATF’s obligations pursuant to Chapter XXIII of the USOC By-Laws. The USATF Athletes Advisory Committee fully supports the principles embodied herein.

2.2 USATF designates USADA to conduct no-advance-notice drug testing of Athletes (See USATF Regulation 10).

2.3. In addition to all the other testing authorized herein, the out-of-competition testing of American Athletes may be conducted by the IAAF pursuant to IAAF Rule 57 and the IAAF Procedural Guidelines for Doping Control. Those Athletes failing to submit to drug testing, after having been notified by the appropriate testing authorities, shall be subject to disciplinary procedures established by USADA and imposed by USATF, pursuant to IAAF Rules (See USATF Regulation 10 and USADA Protocol For Olympic Movement Testing.)

2.4. USATF recognizes USADA’s authority to drug test any USATF athlete, pursuant to its applicable protocols, whether or not said Athlete is a member of USATF’s OOC pool.

**Part III. RANKING LISTS USED FOR SECTION 5.1 EVENTS**

3.1. For the first calendar quarter of each year, the ranking list for each event shall be the previous year’s outdoor list, as available on November 1 of the previous year.

3.2. For the second calendar quarter of each year, the rankings in each
event shall be based on a merged list composed of the previous year’s outdoor list and the current year’s indoor list as available on March 1.

3.3 For the third calendar quarter of each year, the rankings in each event shall be based on a merged list composed of the previous year’s outdoor list, the current year’s outdoor list as available on May 1, and the current year’s indoor list.

3.4 For the fourth calendar quarter of each year, the rankings in each event shall be based on the current year’s outdoor list, as available on August 1.

**Part IV. SELECTION OF ATHLETES FOR DRUG TESTING**

4.1 Athletes shall be selected for drug testing from the OOC Pool by USADA using any method it deems appropriate. Any athlete so selected may be tested by USADA based on that selection, subject to USADA’s rules and procedures, for as long as the athlete remains in the OOC Pool.

4.2 The names of those Athletes who have been banned for life from the sport of track and field, long distance running, and race walking, shall be removed from the OOC Pool. Also, an Athlete with multiple citizenships who has executed a “Surrender of Citizenship Benefits” form, renouncing all claims or entitlement to the privileges and benefits available to track and field athletes who are United States citizens, shall be removed from the OOC Pool. (See copy of “Surrender of Citizenship Benefits” form attached.) An Athlete may resume his/her eligibility to receive benefits available to American athletes if s/he: 1) makes all drug testing results from his/her foreign Track and Field/Athletics Federation available to USATF, and 2) agrees to comply with all applicable International Olympic Committee, United States Olympic Committee, USADA, USATF and/or IAAF eligibility rules, before resuming competition for the United States.

4.3 USADA shall determine the frequency, number, and timing of drug tests as well as the order in which athletes will be tested.

**Part V. TESTED EVENTS**

5.1 TRACK EVENTS:

<table>
<thead>
<tr>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td>100m</td>
<td>100m Hurdles</td>
</tr>
<tr>
<td>200m</td>
<td>400m Hurdles</td>
</tr>
<tr>
<td>400m</td>
<td>3,000m Steeple</td>
</tr>
<tr>
<td>800m</td>
<td></td>
</tr>
<tr>
<td>1,500m/Mile</td>
<td></td>
</tr>
<tr>
<td>5,000m</td>
<td></td>
</tr>
<tr>
<td>10,000m</td>
<td></td>
</tr>
</tbody>
</table>
FIELD EVENTS:

**Women**
- High Jump
- Pole Vault
- Long Jump
- Triple Jump

**Men**
- High Jump
- Pole Vault
- Long Jump
- Triple Jump

**FIELD EVENTS:**

- *Women*  
  - High Jump  
  - Pole Vault  
  - Long Jump  
  - Triple Jump

- *Men*  
  - High Jump  
  - Pole Vault  
  - Long Jump  
  - Triple Jump

MULTIPLE & COMBINED EVENTS:

**Women**
- Heptathlon

**Men**
- Decathlon

RACE WALK:

**Women**
- 20,000m Race Walk

**Men**
- 20,000m Race Walk

5.2 INDOOR ONLY EVENTS:

**Women**
- 60m
- 60m Hurdles
- 3,000m
- Pentathlon

**Men**
- 60m
- 60m Hurdles
- 3,000m
- Heptathlon

5.3 CROSS COUNTRY:

**Women**
- 8,000m

**Men**
- 12,000m

5.4 ROAD RACING:

**Women**
- 10,000m
- Marathon

**Men**
- 10,000m
- Marathon

Part VI. PUBLICATION OF RESULTS

A report of those Athletes testing negative shall be published quarterly by USATF, upon notification from USADA. The names of Athletes found to have committed a doping violation will be published by USADA.

Part VII. AMENDMENTS

7.1. The USATF Board of Directors, by two-thirds vote, may amend this OOC pool selection process. Any such amendment shall not, however, alter USADA’s authority to select any USATF Athlete for testing as provided in Part II, 2.4 above, or any USADA protocol.

7.2. Any changes made to the selection process by the Board of Directors shall be effective immediately, unless otherwise specified.
I, ______________________________, knowingly and with specific intent do hereby surrender my entitlement to compete in track and field events as a United States citizen, in favor of competing for __________, of which I am also a citizen. I understand that by surrendering my eligibility to represent the United States for competition purposes, I will forfeit all benefits to which I would otherwise be entitled as an American athlete member of USA Track & Field, Inc. (USATF), including but not limited to: my ability to compete in USATF national championship competitions, my eligibility to receive American-only prize money awarded at USATF national championships, and my eligibility to receive USATF or United States Olympic Committee grants, insurance and athlete support. In submitting this Surrender of Citizenship Benefits, I understand that I will be removed from USATF’s no-advanced notice drug testing program, and that if I wish to resume my status as a United States track and field athlete at a future date, I will be required to: 1) make all my drug testing results from my other Track and Field/Athletics Federation available to USATF, and 2) comply with all applicable International Olympic Committee, United States Olympic Committee, USATF and/or International Association of Athletics Federations eligibility rules, before resuming competition for the United States. I further understand and agree that this Surrender of Citizenship Benefits is not intended to avoid, nor will it have the effect of avoiding, any disciplinary proceedings that have or will be brought against me pursuant to USATF Regulation 10 for drug testing conducted prior to my surrender of citizenship benefits.

______________ DATE ______________

__________________________
ATHLETE

__________________________
Athlete Signature

STATE OF }

______________

COUNTY OF }

I certify that this document was signed in my presence, by the individual named above, on the date indicated.

______________
Commission Expires

__________________________
Notary Public
Athlete Retirement

Athletes wishing to officially retire from the sport of track & field must complete the required USA Track & Field retirement process.

The athlete must complete an official USA Track & Field Retirement Form, have their signature notarized and mail it to the USATF National Headquarters, attn: Melissa Beasley, 132 E. Washington St., Suite 800, Indianapolis, IN 46204.

In accordance with USATF Regulation 10, updated May 2, 2003, if a retired athlete was ever enrolled in the out-of-competition drug testing program of an international federation, the USOC, or USADA, and said athlete wishes to resume competition, s/he must enroll in the USADA or USATF out-of-competition drug testing pool and be available for testing for a period of at least one year in advance of the date upon which re-eligibility will be granted. Under these circumstances, a retired athlete can only become re-eligible to compete if all drug tests administered during the 12 months preceding the intended eligibility date were negative. Completion of the official USATF retirement form will not suspend or terminate the prosecution or imposition of a sanction related to a doping violation pending prior to giving notice of retirement.

If you have any questions regarding USA Track & Field’s retirement process, please contact Melissa Beasley at 317-713-4650.